# Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

> **NCT01001195** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 165 (actual)

## Conditions studied

- Glaucoma, Open-Angle
- Ocular Hypertension

## Interventions

- **DRUG:** AGN-210669 ophthalmic solution, 0.1%
- **DRUG:** AGN-210669 ophthalmic solution, 0.075%
- **DRUG:** AGN-210669 ophthalmic solution, 0.05%
- **DRUG:** bimatoprost ophthalmic solution 0.03%

## Key facts

- **NCT ID:** NCT01001195
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2013-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01001195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01001195, "Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01001195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*